Remove The Need For Luck When Detecting Low Frequency Variants
Developing innovative technologies which enable early detection, treatment selection
and patient monitoring through confident detection of even the lowest frequency
Cell Free DNA (cfDNA) when extracted is typically of low quantity and the circulating tumor DNA, (ctDNA, tumor derived fraction) is an even smaller fraction of the total cfDNA. Additionally tumor mutations can occur as clonal mutations in all ctDNA or commonly due to tumor heterogeneity as sub-clonal mutations whereby only a small fraction of the ctDNA harbours a given mutation. Therefore exquisitely sensitive tools are required to find these mutations and measure them accurately, this is analogous to finding a 4 leaf clover in a field of clover.
See our range of cfDNA products below.
How Low Can You Go?
Detecting cancer early or monitoring cancer post chemotherapy or surgery requires extremely sensitive analysis due to the small amounts of cfDNA and low fraction of ctDNA content. The Cell3™ Target, targeted NGS kit incorporates error suppression technology including unique molecular indexes (UMI’s) and unique dual indexes (UDI’s) for removal of both PCR / sequencing errors and index hopping events. This allows confident and sensitive calling of mutations down to 0.1% VAF and from as little as 10ng ctDNA input.
Cell3™ Target: Pan-Cancer TMB/MSI (524) Panel
A comprehensive panel of 524 oncogenes that allows you to accurately profile and stratify all common cancers and predict response to immunotherapy.
All in one assay.
Cell3™ Target: Actionable Mutation Panel (EGRF)
A highly focused panel covering actionable mutations in the EGFR pathway. As it’s validated on ctDNA as well as FF and FFPE DNA it offers a quick and affordable method for profiling primary tumors and/or liquid biopsies.